Supplementary Figure S1. Overall survival after initiation of immune checkpoint inhibitor treatment in patients with and without irAEs other than endocrine-irAEs.

Overall survival (OS) of patients with non-small cell lung carcinoma (NSCLC) (A, C, E, G) or malignant melanoma (MM) (B, D, F, H). Solid and dashed lines indicate OS of patients who did and did not develop each irAE, respectively. In patients with NSCLC, there were no differences in OS between patients who developed any non-Endo-irAEs (A), lung-irAE (C), skin-irAE (E) or GI-irAE (G) and those who did not. In patients with MM, there were no differences in OS between patients who developed any non-Endo-irAEs (B), lung-irAE (D), skin-irAE (F) or GI-irAE (H) and those who did not.